OBJECTIVES: We evaluated an intervention designed to identify patients at risk for hepatitis C virus (HCV) through a risk screener used by primary care providers. METHODS: A clinical reminder sticker prompted physicians at 3 urban clinics to screen patients for 12 risk factors and order HCV testing if any risks were present. Risk factor data were collected from the sticker; demographic and testing data were extracted from electronic medical records. We used the t test, χ(2) test, and rank-sum test to compare patients who had and had not been screened and developed an analytic model to identify the incremental value of each element of the screener. RESULTS: Among screened patients, 27.8% (n = 902) were identified as having at least 1 risk factor. Of screened patients with risk factors, 55.4% (n = 500) were tested for HCV. Our analysis showed that 7 elements (injection drug use, intranasal drug use, elevated alanine aminotransferase, transfusions before 1992, ≥ 20 lifetime sex partners, maternal HCV, existing liver disease) accounted for all HCV infections identified. CONCLUSIONS: A brief risk screener with a paper-based clinical reminder was effective in increasing HCV testing in a primary care setting.
OBJECTIVES: We evaluated an intervention designed to identify patients at risk for hepatitis C virus (HCV) through a risk screener used by primary care providers. METHODS: A clinical reminder sticker prompted physicians at 3 urban clinics to screen patients for 12 risk factors and order HCV testing if any risks were present. Risk factor data were collected from the sticker; demographic and testing data were extracted from electronic medical records. We used the t test, χ(2) test, and rank-sum test to compare patients who had and had not been screened and developed an analytic model to identify the incremental value of each element of the screener. RESULTS: Among screened patients, 27.8% (n = 902) were identified as having at least 1 risk factor. Of screened patients with risk factors, 55.4% (n = 500) were tested for HCV. Our analysis showed that 7 elements (injection drug use, intranasal drug use, elevated alanine aminotransferase, transfusions before 1992, ≥ 20 lifetime sex partners, maternal HCV, existing liver disease) accounted for all HCV infections identified. CONCLUSIONS: A brief risk screener with a paper-based clinical reminder was effective in increasing HCV testing in a primary care setting.
Authors: Alain H Litwin; Bryce D Smith; Mari-Lynn Drainoni; Diane McKee; Allen L Gifford; Elisa Koppelman; Cindy L Christiansen; Cindy M Weinbaum; William N Southern Journal: Dig Liver Dis Date: 2012-02-18 Impact factor: 4.088
Authors: F Tumminelli; P Marcellin; S Rizzo; S Barbera; G Corvino; P Furia; J P Benhamou; S Erlinger Journal: Lancet Date: 1995-03-11 Impact factor: 79.321
Authors: C Conry-Cantilena; M VanRaden; J Gibble; J Melpolder; A O Shakil; L Viladomiu; L Cheung; A DiBisceglie; J Hoofnagle; J W Shih Journal: N Engl J Med Date: 1996-06-27 Impact factor: 91.245
Authors: Andrew D Schreiner; John Bian; Jingwen Zhang; Z Merle Haulsee; Justin Marsden; Valerie Durkalski-Mauldin; Patrick D Mauldin; William P Moran; Don C Rockey Journal: Am J Med Date: 2019-07-29 Impact factor: 4.965
Authors: Brianna L Norton; William N Southern; Meredith Steinman; Bryce D Smith; Joseph Deluca; Zachary Rosner; Alain H Litwin Journal: Clin Gastroenterol Hepatol Date: 2016-04-19 Impact factor: 11.382
Authors: Danielle Liffmann Kruger; David B Rein; Natalie Kil; Cynthia Jordan; Kimberly A Brown; Anthony Yartel; Bryce D Smith Journal: Health Promot Pract Date: 2016-08-19
Authors: Bryce D Smith; Geoff A Beckett; Anthony Yartel; Deborah Holtzman; Nita Patel; John W Ward Journal: Am J Public Health Date: 2014-01-16 Impact factor: 9.308
Authors: Joanne E Brady; Danielle K Liffmann; Anthony Yartel; Natalie Kil; Alex D Federman; Joseph Kannry; Cynthia Jordan; Omar I Massoud; David R Nerenz; Kimberly A Brown; Bryce D Smith; Claudia Vellozzi; David B Rein Journal: Hepatology Date: 2016-11-25 Impact factor: 17.425
Authors: Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely Journal: Liver Int Date: 2018-09-22 Impact factor: 5.828
Authors: Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore Journal: Int J Drug Policy Date: 2015-07-17
Authors: Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore Journal: Int J Drug Policy Date: 2017-07-03